Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Metabolism
  4. Volume 25, Issue 6
  5. Article
Volume 25, Issue 6
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Background

Everolimus is a drug approved for the treatment of breast cancer with HR+ and advanced breast cancer reoccurring in postmenopausal women. The oral administration of EVE has been observed to have low oral bioavailability and severe epithelial cutaneous events that include rashes and lip ulceration followed by mouth ulceration after oral administration.

Aim

The present research aimed to enhance the bioavailability by loading the EVE into a stealth liposomal formulation (S-EVE-LIPO) intended for intravenous administration.

Methods

The surface of the liposomes was modified with vitamin E TPGS, which prolongs the systemic circulation of the drug and provides additional benefits like inhibition of the P-gp efflux pump and acting synergistically with EVE.

Results

The formulation was prepared using the thin film hydration method and optimized using a D-optimal mixture design. ANOVA suggested the significance of the proposed mathematic model, and the optimized formulation was generated by design expert software. The optimized formulation (S-EVE-LIPO) was observed with nanometric size (99.5 ± 3.70 nm) with higher encapsulation efficacy (81.5 ± 2.86%). The S-EVE-LIPO formulation indicated a sustained release profile as 90.22% drug release was observed in 48 h, whereas the formulation without vitamin E TPGS (EVE-LIPO) released only 74.15 drugs in 24 hours. cytotoxicity study suggested that the presence of vitamin E TPGS lowers the IC value (54.2 ± 1.69), increases the cellular uptake of the formulation, also increases the generation of ROS, and shows better hemocompatibility.

Conclusion

Vitamin E TPGS could be set as a vital additive to improve therapeutic efficacy and reduce off-site toxicity and dosing frequency.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002322171240821104152
2024-08-27
2025-01-06

  • From This Site

    /content/journals/cdm/10.2174/0113892002322171240821104152
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WaksA.G. WinerE.P. Breast cancer treatment.JAMA2019321331610.1001/jama.2018.20751 30667503
     [Google Scholar]
  2. KaurS. SinghD. Resveratrol-exemestane beneficial regimen to overcome the complications over existing therapies for the management of breast cancer.Curr. Mol. Med.2023 36918787
     [Google Scholar]
  3. SiegelR.L. GiaquintoA.N. JemalA. Cancer statistics, 2024.CA Cancer J. Clin.2024741124910.3322/caac.21820 38230766
     [Google Scholar]
  4. RugoH.S. PritchardK.I. GnantM. NoguchiS. PiccartM. HortobagyiG. BaselgaJ. PerezA. GeberthM. CsosziT. ChouinardE. SrimuninnimitV. PuttawibulP. EakleJ. FengW. BaulyH. El-HashimyM. TaranT. BurrisH.A.III Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2.Ann. Oncol.201425480881510.1093/annonc/mdu009 24615500
     [Google Scholar]
  5. SendurM.A.N. ZenginN. AksoyS. AltundagK. Everolimus: A new hope for patients with breast cancer.Curr. Med. Res. Opin.2014301758710.1185/03007995.2013.846253 24050600
     [Google Scholar]
  6. MaY. GuanR. GaoS. SongW. LiuY. YangY. LiuH. Designing orodispersible films containing everolimus for enhanced compliance and bioavailability.Expert Opin. Drug Deliv.202017101499150810.1080/17425247.2020.1828342 32975132
     [Google Scholar]
  7. AaproM. AndreF. BlackwellK. CalvoE. JahanzebM. PapazisisK. PortaC. PritchardK. RavaudA. Adverse event management in patients with advanced cancer receiving oral everolimus: Focus on breast cancer.Ann. Oncol.201425476377310.1093/annonc/mdu021 24667713
     [Google Scholar]
  8. KaurS. SinghD. A sojourn on liposomal delivery system: Recent advances and future prospects.Assay Drug Dev. Technol.2023212486410.1089/adt.2022.089 36856471
     [Google Scholar]
  9. MozarF.S. ChowdhuryE.H. Impact of PEGylated nanoparticles on tumor targeted drug delivery.Curr. Pharm. Des.201824283283329610.2174/1381612824666180730161721 30062957
     [Google Scholar]
  10. GuoY. LuoJ. TanS. OtienoB.O. ZhangZ. The applications of vitamin E TPGS in drug delivery.Eur. J. Pharm. Sci.201349217518610.1016/j.ejps.2013.02.006 23485439
     [Google Scholar]
  11. LiN. MaiY. LiuQ. GouG. YangJ. Docetaxel-loaded D-α-tocopheryl polyethylene glycol-1000 succinate liposomes improve lung cancer chemotherapy and reverse multidrug resistance.Drug Deliv. Transl. Res.202111113114110.1007/s13346‑020‑00720‑9 32052357
     [Google Scholar]
  12. SandalP. PatelP. SinghD. GuptaG.D. KurmiB.D. α-Tocopherol polyethylene glycol 1000 succinate-based cationic liposome for the intracellular delivery of doxorubicin in MDA-MB-231 triple-negative breast cancer cell line.Assay Drug Dev. Technol.202321834535610.1089/adt.2023.067 38010987
     [Google Scholar]
  13. LiuS. SongX.L. WangY.H. WangX.M. XiaoY. WangX. ChengL. LiX.T. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.J. Drug Target.201725654155310.1080/1061186X.2017.1298602 28277825
     [Google Scholar]
  14. MengJ. GuoF. XuH. LiangW. WangC. YangX.D. Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo.Sci. Rep.2016612239010.1038/srep22390 26947928
     [Google Scholar]
  15. AğardanN.B.M. DeğimZ. YılmazŞ. AltıntaşL. TopalT. Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer.J. Drug Deliv. Sci. Technol.20205710161210.1016/j.jddst.2020.101612
     [Google Scholar]
  16. KushwahV. JainD.K. AgrawalA.K. JainS. Improved antitumor efficacy and reduced toxicity of docetaxel using anacardic acid functionalized stealth liposomes.Colloids Surf. B Biointerfaces201817221322310.1016/j.colsurfb.2018.08.047 30172202
     [Google Scholar]
  17. PooniaN. Kaur NarangJ. LatherV. BegS. SharmaT. SinghB. PanditaD. Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation.Colloids Surf. B Biointerfaces201918175676610.1016/j.colsurfb.2019.06.004 31234063
     [Google Scholar]
  18. ZhaoY.N. CaoY.N. SunJ. LiangZ. WuQ. CuiS.H. ZhiD.F. GuoS.T. ZhenY.H. ZhangS.B. Anti-breast cancer activity of resveratrol encapsulated in liposomes.J. Mater. Chem. B Mater. Biol. Med.202081273710.1039/C9TB02051A 31746932
     [Google Scholar]
  19. RanjeethaM. NiranjanM. ChaluvarajuK. MamathaM. DarshithaR. VarshaC. New derivative spectroscopic method for the estimation of axitinib and everolimus in bulk and physical mixture.J. Chem. Pharm. Res.20181056166
     [Google Scholar]
  20. NeupaneY.R. SrivastavaM. AhmadN. KumarN. BhatnagarA. KohliK. Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment.Int. J. Pharm.20144771-260161210.1016/j.ijpharm.2014.11.001 25445972
     [Google Scholar]
  21. ChenY. ChenJ. ChengY. LuoL. ZhengP. TongY. LiZ. A lyophilized sterically stabilized liposome-containing docetaxel: In vitro and in vivo evaluation.J. Liposome Res.2017271647310.3109/08982104.2016.1158185 27031365
     [Google Scholar]
  22. XuY. MengH. Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.Artif. Cells Nanomed. Biotechnol.201644135035510.3109/21691401.2014.951722 25162671
     [Google Scholar]
  23. KurmiB.D. PaliwalR. PaliwalS.R. Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: A quality by design approach.Int. J. Biol. Macromol.20201642881289410.1016/j.ijbiomac.2020.08.172 32853621
     [Google Scholar]
  24. SinghA. ThakurS. SinghH. SinghH. KaurS. KaurS. DudiR. MondheD.M. JainS.K. Novel vitamin E TPGS based docetaxel nanovesicle formulation for its safe and effective parenteral delivery: Toxicological, pharmacokinetic and pharmacodynamic evaluation.J. Liposome Res.202131436538010.1080/08982104.2020.1835955 33050745
     [Google Scholar]
  25. HanS.M. BaekJ.S. KimM.S. HwangS.J. ChoC.W. Surface modification of paclitaxel-loaded liposomes using d-α-tocopheryl polyethylene glycol 1000 succinate: Enhanced cellular uptake and cytotoxicity in multidrug resistant breast cancer cells.Chem. Phys. Lipids2018213394710.1016/j.chemphyslip.2018.03.005 29550143
     [Google Scholar]
  26. SinghA. NeupaneY.R. ShafiS. ManglaB. KohliK. PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: In vitro and in vivo assessment.J. Mol. Liq.202030311264910.1016/j.molliq.2020.112649
     [Google Scholar]
  27. ChandelS. BhattacharyaA. GautamA. ZengW. AlkaO. SachsenbergT. GuptaG.D. NarangR.K. RavichandiranV. SinghR. Investigation of the anti-cancer potential of epoxyazadiradione in neuroblastoma: Experimental assays and molecular analysis.J. Biomol. Struct. Dyn.202311910.1080/07391102.2023.2262593 37753734
     [Google Scholar]
  28. RajuA. MuthuM.S. FengS.S. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel.Expert Opin. Drug Deliv.201310674776010.1517/17425247.2013.777425 23458409
     [Google Scholar]
  29. LiN. FuT. FeiW. HanT. GuX. HouY. LiuY. YangJ. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells.J. Pharm. Pharmacol.20197181243125410.1111/jphp.13126 31215039
     [Google Scholar]
  30. JainS. JainR. DasM. AgrawalA.K. ThankiK. KushwahV. Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity.RSC Advances2014455291932920110.1039/C4RA04237A
     [Google Scholar]
  31. SinghR. ChandelS. GhoshA. MattaT. GautamA. BhattacharyaA. BabuS.S. SuklaS. NagD. RavichandiranV. RoyS. GhoshD. Glucogallin attenuates the LPS-induced signaling in macrophages and protects mice against sepsis.Int. J. Mol. Sci.202223191125410.3390/ijms231911254 36232563
     [Google Scholar]
  32. KhanA.N. SinghR. BhattacharyaA. KumarS. GhoshA. NagD. RavichandiranV. GhoshD. Glucogallin attenuates RAW 264.7 cells from arsenic trioxide induced toxicity via the NF-ҡB/NLRP3 pathway.Molecules20222716526310.3390/molecules27165263 36014502
     [Google Scholar]
  33. KangY. MaoZ. WangY. PanC. OuM. ZhangH. ZengW. JiX. Design of a two-dimensional interplanar heterojunction for catalytic cancer therapy.Nat. Commun.2022131242510.1038/s41467‑022‑30166‑1 35504879
     [Google Scholar]
  34. YuanX. KangY. DongJ. LiR. YeJ. FanY. HanJ. YuJ. NiG. JiX. MingD. Self-triggered thermoelectric nanoheterojunction for cancer catalytic and immunotherapy.Nat. Commun.2023141514010.1038/s41467‑023‑40954‑y 37612298
     [Google Scholar]
  35. AyazS. GuptaS. SinghR. KurmiB.D. AlmehiziaA.A. AsatiV. Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents.J. Mol. Struct.2024131113830110.1016/j.molstruc.2024.138301
     [Google Scholar]
  36. ChandelS. SinghR. GautamA. RavichandiranV. Screening of Azadirachta indica phytoconstituents as GSK-3β inhibitor and its implication in neuroblastoma: Molecular docking, molecular dynamics, MM-PBSA binding energy, and in-vitro study.J. Biomol. Struct. Dyn.20224023128271284010.1080/07391102.2021.1977705 34569452
     [Google Scholar]
  37. KatharotiyaK. ShindeG. KatharotiyaD. ShelkeS. PatelR. KulkarniD. PanzadeP. Development, evaluation and biodistribution of stealth liposomes of 5-fluorouracil for effective treatment of breast cancer.J. Liposome Res.202232214615810.1080/08982104.2021.1905661 33847220
     [Google Scholar]
  38. MakiM.A.A. KumarP.V. CheahS.C. Siew WeiY. Al-NemaM. BayazeidO. MajeedA.B.B.A. Molecular modeling-based delivery system enhances everolimus-induced apoptosis in Caco-2 cells.ACS Omega2019458767877710.1021/acsomega.9b00109 31459966
     [Google Scholar]
  39. KurmiB.D. PaliwalS.R. Development and optimization of TPGS-based stealth liposome of doxorubicin using Box–Behnken design: Characterization, hemocompatibility, and cytotoxicity evaluation in breast cancer cells.J. Liposome Res.202232212914510.1080/08982104.2021.1903034 33724151
     [Google Scholar]
  40. BanerjeeP. GengT. MahantyA. LiT. ZongL. WangB. Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors.Int. J. Pharm.201955737438910.1016/j.ijpharm.2018.12.051 30610896
     [Google Scholar]
  41. ZhangJ. TaoW. ChenY. ChangD. WangT. ZhangX. MeiL. ZengX. HuangL. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy.J. Mater. Sci. Mater. Med.201526416510.1007/s10856‑015‑5498‑z 25791459
     [Google Scholar]
  42. RathodS. BahadurP. TiwariS. Nanocarriers based on vitamin E-TPGS: Design principle and molecular insights into improving the efficacy of anticancer drugs.Int. J. Pharm.202159212004510.1016/j.ijpharm.2020.120045 33212172
     [Google Scholar]
  43. MuL. FengS.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS.J. Control. Release2003861334810.1016/S0168‑3659(02)00320‑6 12490371
     [Google Scholar]
  44. SinghM. RanaN.K. MuthuM.S. JhaA. Basu BaulT.S. KochB. Enhanced in vitro therapeutic efficacy of triphenyltin (IV) loaded vitamin E TPGS against breast cancer therapy.Mater. Today Commun.20223110325610.1016/j.mtcomm.2022.103256
     [Google Scholar]
  45. AnwerK.E. El-SattarN.E.A.A. ShamaaM.M. ZakariaM.Y. BeshayB.Y. Design, green synthesis and tailoring of vitamin E TPGS augmented niosomal nano-carrier of pyrazolopyrimidines as potential anti-liver and breast cancer agents with accentuated oral bioavailability.Pharmaceuticals202215333010.3390/ph15030330 35337128
     [Google Scholar]
  46. MiY. LiuY. FengS.S. Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy.Biomaterials201132164058406610.1016/j.biomaterials.2011.02.022 21396707
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002322171240821104152
Loading
Quality by Design-Steered Development of Stealth Liposomal Formulation of Everolimus: A Systematic Optimization and Evaluation
Current Drug Metabolism 25, 446 (2024); https://doi.org/10.2174/0113892002322171240821104152
/content/journals/cdm/10.2174/0113892002322171240821104152
/content/journals/cdm/10.2174/0113892002322171240821104152
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): breast cancer; cytotoxicity; Everolimus; liposomes; MCF-7 cell lines; mixture design

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test